# Clinical Validation of Medasense Pain Response Index (PRI)

> **NCT01762332** · NA · COMPLETED · sponsor: **Medasense Biometrics Ltd** · enrollment: 82 (actual)

## Conditions studied

- Surgery
- Pain

## Interventions

- **DRUG:** Base level of remifentanil effect side concentration: 2ng/ml
- **DRUG:** Base level of remifentanil effect side concentration: 4ng/ml
- **OTHER:** chronic beta-blocker treatment

## Key facts

- **NCT ID:** NCT01762332
- **Lead sponsor:** Medasense Biometrics Ltd
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-01
- **Primary completion:** 2014-05
- **Final completion:** 2014-05-25
- **Target enrollment:** 82 (ACTUAL)
- **Last updated:** 2019-03-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01762332

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01762332, "Clinical Validation of Medasense Pain Response Index (PRI)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01762332. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*